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Noonan syndrome (NS) is characterised by distinctive facial features, heart defects, variable
degrees of intellectual disability and other phenotypic manifestations. Although the mode of
inheritance is typically dominant, recent studies indicate LZTR1 may be associated with both dom-
inant and recessive forms. Seeking to describe the phenotypic characteristics of LZTR1-associated
NS, we searched for likely pathogenic variants using two approaches. First, scrutiny of exomes
from 9624 patients recruited by the Deciphering Developmental Disorders (DDDs) study uncov-
ered six dominantly-acting mutations (p.R97L; p.Y136C; p.Y136H, p.N145I, p.S244C; p.G248R) of
which five arose de novo, and three patients with compound-heterozygous variants (p.R210*/p.
V579M; p.R210*/p.D531N; c.1149+1G>T/p.R688C). One patient also had biallelic loss-of-
function mutations in NEB, consistent with a composite phenotype. After removing this complex
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case, analysis of human phenotype ontology terms indicated significant phenotypic similarities
(P = 0.0005), supporting a causal role for LZTR1. Second, targeted sequencing of eight unsolved
NS-like cases identified biallelic LZTR1 variants in three further subjects (p.W469*/p.Y749C, p.
W437*/c.-38T>A and p.A461D/p.I462T). Our study strengthens the association of LZTR1 with
NS, with de novo mutations clustering around the KT1-4 domains. Although LZTR1 variants
explain ~0.1% of cases across the DDD cohort, the gene is a relatively common cause of unsolved
NS cases where recessive inheritance is suspected.
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1 | INTRODUCTION
Noonan syndrome (NS) is a multisystem condition caused by dys-
regulation of RAS-MAPK signalling. Clinical features include a charac-
teristic facial gestalt (broad forehead, hypertelorism, downslanting
palpebral fissures, ptosis, small chin), posteriorly-rotated, low-set ears,
webbing of the neck, widely-spaced nipples, undescended testes and
short stature.1–3 Skeletal abnormalities can include pectus mal-
formations, spinal deformities and cubitus valgus. Heart defects such
as pulmonary stenosis or hypertrophic cardiomyopathy occur in a sub-
stantial fraction of patients and the association with intellectual dis-
ability has long been recognized.2,4,5 The NS phenotype is extremely
variable and not all features are observed in all patients. Heterogene-
ity also exists within families and many mildly affected adults remain
undiagnosed until the birth of a more severely affected child. The oft
quoted incidence rate of 1/1000-1/2500 live births5 may therefore
be an underestimate.
PTPN11 encodes a protein tyrosine phosphatase implicated in
RAS-MAPK signalling and was the first gene associated with NS,
responsible for ~50% of cases.6 Several other NS genes with roles in
RAS-MAPK signalling have subsequently been identified. These
include KRAS, SOS1, RAF1, NRAS, BRAF, RIT1 and SOS2.7 Despite
these gene discovery efforts, a small but significant fraction of cases
remain mutation-negative for known genes.
In contrast to other studies which concentrated on components
of RAS-MAPK signalling,8 unbiased exome sequencing of two large
Brazilian kindreds identified LZTR1 as the only gene harbouring rare,
predicted-deleterious variants co-segregating with NS consistent with
an autosomal dominant (AD) mode of inheritance.9 Identification of
three smaller families with mutations clustering around the same
protein-interaction domains supported LZTR1 as a novel NS gene
(MIM#616564).
Until recently, the mode of inheritance associated with NS has
exclusively been AD, with mutations arising de novo or inherited from
affected parents. Although sibling recurrence is occasionally seen in
families where parents are unaffected, such findings are typically
thought to be the result of genetic mosaicism.10 Indeed, PTPN11
mutations undergo positive selection during spermatogenesis.11,12
Nevertheless, speculation that an autosomal recessive (AR) form of
NS exists, first proposed >25 years ago,13 has persisted, supported by
the description of NS patients from consanguineous kindreds
(MIM#605275; NS2).14
A 2018 study involving two large NS families where AR inheri-
tance was considered likely identified overlapping linkage regions
each harbouring rare biallelic variants in LZTR1. Ten further families
were identified, making a total of 23 affected individuals with biallelic
alterations.15 In this study, we sought to identify patients with LZTR1-
associated NS across a well-defined clinical cohort by performing a
systematic analysis of 9624 exomes from the Deciphering Develop-
mental Disorders (DDDs) study. In addition, we used a targeted
sequencing approach, selecting clinically diagnosed NS families in
whom AR inheritance was considered likely, and performed detailed
phenotyping on all affected individuals to help delineate the
phenotypic/genotypic ranges of these conditions.
2 | MATERIALS AND METHODS
2.1 | Informed consent and exome sequencing
All patients described here (or their parents/legal representative) gave
informed consent to participate in this study. The DDD study (www.
ddduk.org) focuses on children with undiagnosed developmental dis-
orders and aims to develop translational genomics workflows to feed-
back potentially diagnostic findings.16 Patients were recruited from
the 24 Regional Genetics Services in the UK and Republic of Ireland
under Research Ethics Committee approval (10/H0305/83; Cam-
bridge South REC, and GEN/284/12; Republic of Ireland REC). Exome
sequencing methods have been described previously.16 Data analysis
involved mapping reads to hs37d5 and calling variants with
GATK/CoNVex. De novo variants were called using DeNovoGear.
The analysis described here was performed on a data freeze
corresponding to 7832 parent-parent-child trios and 1792 patient
singletons.
2.2 | Data availability
Data is accessible from the EGA archive (https://ega-archive.org/;
EGAS00001000775.)
2.3 | Variant filtering
Candidate variants in 9624 probands were identified across all genes
using the following steps:
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1. Minor allele frequency (MAF) was restricted to <0.1% for pro-
bands analysed as part of parent-child trios. This was reduced
to <0.01% (ExAC allele count of <5) for dominant variants in
singletons. Hemizygous variants had a maximum MAF of
<0.1% in trios/singletons and an ExAC hemizygous count = 0.
For recessive variants, MAF was required to be <1% in
trios/singletons.
2. Annotation using VEP17 had to predict the most severe conse-
quence to be a loss-of-function or protein-altering change.
Inherited variants predicted benign by PolyPhen2 were excluded.
Deletions/duplications had to be >1 Mb.
3. The genotypes and observed inheritance pattern had to be consis-
tent with dominant, recessive or X-linked modes of inheritance
Candidate variants were then interrogated, looking for specific
patients where there was at least one qualifying variant in LZTR1. For
such cases, we obtained vcf files, filtered lists of all candidate variants
in that individual, information about previously reported SNV/indels/-
CNVs and detailed clinical data.
2.4 | Analysis of human phenotype ontology terms
Clinical information was collected using human phenotype ontology
(HPO), a standardized vocabulary of phenotypic abnormalities (http://
human-phenotype-ontology.github.io/). The significance of pheno-
typic similarity between LZTR1-positive patients was estimated by
comparing similarity of HPO terms between the patients of interest to
that between randomly selected patients from the diverse DDD
cohort, as described.18,19
2.5 | Sanger sequencing, allele-specific PCR and
relationship confirmation
PCR amplification of LZTR1 was performed as described in Table S1.
An additional amplicon was included to capture intron 16 where var-
iants can lead to retention of an alternative exon.15 Following enzy-
matic purification, Sanger sequencing was performed using BigDye
(version 3.1) and the ABI 3730XL (Applied Biosystems, Foster City,
California).
Where parental samples were unavailable, compound-
heterozygous variants were phased by allele-specific PCR whereby
the 30-base of the first primer was complementary to either the wild-
type or mutant allele (Table S1). Sanger sequencing was then per-
formed to determine the sequence at the second locus. A similar
method was used to phase a de novo variant where the closest infor-
mative SNP was too distant to be phased by Illumina read-pairs
(Table S1).
For one family where the patient underwent exome sequenc-
ing as a singleton, maternity/paternity were confirmed by
genotyping nine short tandem repeat (STR) loci using the
AuthentiFiler PCR Amplification Kit (ThermoFisher Scientific, Wal-
tham, Massachusetts).
3 | RESULTS
3.1 | Four likely-pathogenic de novo LZTR1 variants
identified in patient-parent trios
Among 7832 parent-parent-child trios, exome sequencing uncovered
five patients with de novo missense mutations in LZTR1, all called with
high confidence (posterior probability for the de novo configuration,
pp_dnm >0.9). Of these, four clustered around kelch domains KT1-4
(codons 79-285, UniProt Q8N653), had CADD scores of 26-34 and
thus were deemed likely pathogenic. More genetic information and
clinical characteristics of these patients are in Table 1, Table S2 and
Figure 1A-C. The 5th de novo variant (c.2074T>G; p.F692V) lies out-
side KT1-4 and a hemizygous RPS6KA3 variant provides a better
explanation for the phenotype (https://decipher.sanger.ac.
uk/patient/266615).
Patient 303983 harbored a de novo c.290G>T; p.R97L variant
(NM_006767.3) within the KT1 domain of LZTR1 (Figure 2A). She
was recruited to DDD with suspected NS but PTPN11 and several
other NS genes were mutation-negative. Clinical features include a
typical NS gestalt (Figures 1A and S1A), hypertrophic cardiomyopathy,
a ventricular septal defect and short stature. She is planning to have
surgery on her spine due to kyphosis and anterior fusion of T9-12
intervertebral discs.
Patient 287232 harbored a de novo c.407A>G; p.Y136C variant
within KT2 (Figure 2B). Hypotonic at birth, this boy has a classical NS
gestalt, with coarse facial features, left-sided congenital ptosis, low-
set ears, pointed chin and pectus excavatum (Figures 1B and S1B). He
has mild pulmonary valve stenosis, short stature and developmental
delay (particularly affecting motor skills).
Patient 274799 harbored a de novo c.731C>G; p.S244C variant
within KT4 (Figure 2C). This boy had low-set, posteriorly rotated ears,
webbing of the neck and pectus carinatum, leading to a strong clinical
suspicion of NS. Mutations in PTPN11 and several other NS genes
had previously been excluded.
Patient 278971 harbored a nearby de novo variant (c.742G>A; p.
G248R, Figure 2C), also within KT4. Here, the de novo configuration
was less certain (pp_dnm = 0.93) but later confirmed by Sanger
sequencing of patient/parental DNA. Unlike the other de novo vari-
ants identified, p.G248R was reported in gnomAD as a singleton
(Table 1) and in two independent NS families.9,20 Patient 278971's
most significant clinical issues relate to perinatal asphyxia. She had
seizures in the neonatal period, which resolved for a period of time
but later recurred. Aged 8 years, she weighs only 16 kg. She attends a
special school, cannot read or write, walks only with an aid/frame and
has extremely limited speech. She had successful mitral valve surgery
3 years ago to control regurgitation. She now has marked
micrognathia such that intubation is always an ordeal. Although she
had/has features within the NS spectrum such as low-set ears, neck
webbing, pectus excavatum and mild cubitus valgus, facial features
are now atypical for NS (Figures 1C and S1C). No additional clinically
relevant genetic variants were identified and so we speculate that her
phenotype may have been complicated by antenatal/perinatal insults
which have resulted in severe intellectual disability and growth
restriction.
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FIGURE 1 Clinical images showing Noonan-like features in patients where consent was obtained. A, Patient 303983 aged 7.5 and 14 years
showing hypertelorism and low-set posteriorly rotated ears. B, Patient 287232 aged 5 years showing low-set ears, pointed chin and pectus
excavatum. C, Patient 278971 shown at 11 months and 3.7 years showing epicanthic folds and depressed nasal bridge and D, Patient 272332
aged 8.6 years and 10.2 years with interrupted eyebrow, long palpebral fissures, low-set posteriorly rotated ears, thin top lip and narrow chin. E,
Patient 279914 aged 6.8 years showing a convergent squint, ptosis, low-set posteriorly rotated ears and wide neck. F, Patient 284672 aged
8 years showing long face, hypertelorism, proptosis, downslanting palpebral fissures, retrognathia, macrodontia and a high, narrow palate. G,
Patient 284673 (284672's elder sister) aged 11 years—while both siblings had biallelic NEB variants, the elder sister did not have both LZTR1
variants and so is shown for comparison. Although both sisters have myopathy and bilateral ptosis, the younger sibling has a stronger NS
gestalt. H, Patient O1409410 aged 12 years showing down-slanting palpebral fissures, palpebral ptosis, low-set posteriorly rotated ears and fetal
finger-tip pads. I, Patient O1409412 aged 28 years showing a narrow nasal root and broad nasal tip
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3.2 | Analysis of singleton exomes identifies
additional de novo/inherited variants
A qualifying heterozygous variant in LZTR1 was identified in
25/1792 singleton exomes (Table S3). Of these, two were missense
changes involving KT1-4, both absent from gnomAD. The first of
these was a heterozygous c.406T>C; p.Y136H alteration in female
patient 269172 with significant cardiac abnormalities. The variant
notably disrupts the same codon as the de novo c.407A>G; p.
Y136C. We subsequently validated the variant (Figure 2B) and con-
firmed its absence from parental DNAs, consistent with it having
arisen de novo. In contrast, six other rare candidate variants
observed in 269172 were inherited from unaffected parents
(Table S4). Together with data from nine STRs, these results helped
confirm maternity/paternity. This patient's main clinical issues are
cardiac and include severe pre-ductal coarctation, bicuspid aortic
valve, “parachute” mitral valve and left atrial isomerism. Although
there is a mild NS-like gestalt, this was more prominent earlier in
development.
The second notable variant in a singleton was c.434A>T; p.
N145I in patient 271777 (III-4). His phenotype included global
developmental delay, learning difficulties, drooling, hyperreflexia,
hypertonia, periventricular leukomalacia and an abnormal/myopathic
long facial shape; in childhood it was suggested that he may have
NS. The same variant was detected independently in a first cousin
(III-1) using exome sequencing and a virtual RASopathy gene-panel.
III-1 has mild pulmonary stenosis, mild learning difficulties, a
webbed neck and facial features reminiscent of NS. A fuller descrip-
tion of this family and results of segregation testing in other mildly
affected family members is presented in Supporting Information,
Supplementary note 1.
FIGURE 2 Sanger validation of de novo mutations and distribution of autosomal dominant and recessive variants across LZTR1. A, Validation
data for the c.290G>T; p.R97L variant. B, Validation data for two de novo variants that disrupt Tyr136. C, Validation data for de novo variants
disrupting Ser244/Gly248 alongside other variants reported to be associated with Noonan syndrome (NS). D, Distribution of variants identified in
this study along the LZTR1 protein. Figure adapted from protein summary view at DECIPHER (https://decipher.sanger.ac.
uk/gene/LZTR1#overview/protein-info). Likely loss of function variants shown in red, missense and 5’-UTR variants shown in green
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3.3 | Phasing of de novo mutations
In the four cases where likely pathogenic de novo variants (p.R97L,
p.Y136C, p.S244C, p.G248R) were identified by trio exome
sequencing, informative intronic SNPs were identified 68 bp-136 bp
away (Table S5). For singleton patient 269172, the closest identifi-
able informative SNP was >5 kb away, so phasing of the p.Y136C
mutation was performed using allele-specific PCR (Table S1). In all
five cases, the de novo variant had arisen on the paternal chromo-
some (Table S5).
3.4 | Recessive LZTR1 cases and a “blended”
phenotype of NS and nemaline myopathy
Three unrelated individuals harbouring biallelic variants in LZTR1 were
found. These individuals were also identified in a global analysis of the
DDD cohort that sought to identify novel disease genes in addition to
quantifying the overall contribution of recessive variants to develop-
mental disorders.19 The variants identified were all rare, with gnomAD
MAFs of 1/241846 to 19/276182 and CADD scores of 23 to
40 (Table 1). Additional information for these patients is shown in
Table S6 and Figure 1D-F.
Patient 272332 inherited a c.1591G>A; p.D531N variant in trans
with c.628C>T; p.R210*. An unaffected brother only harbored the
p.D531N variant. Using the ACMG criteria for assessing
pathogenicity,21 p.D531N is ranked as a variant of uncertain signifi-
cance (VUS, Table S7). Cardiac features included hypertrophic cardio-
myopathy and mitral valve prolapse, requiring surgery; these led to NS
being considered as a potential diagnosis. Prior testing of PTPN11 was
negative. Although this male patient had low-set, posteriorly rotated
ears, a narrow chin, foetal fingertip pads and short stature, the facial
features of this patient were considered to be more suggestive of
Kabuki syndrome (Figures 1D and S1D). He has moderate to severe
intellectual disability, autism spectrum disorder and tonic-clonic sei-
zures which recently returned, aged 14 years.
Patient 279914 inherited a splice donor site variant (c.1149
+1G>T) and a c.2062C>T; p.R688C. Although prior testing for
PTPN11 and other NS genes was negative, the patient had a pre-
sumed NS diagnosis, with notable features including blue irides,
downslanting palpebral fissures, hypertelorism, low-set posteriorly
rotated ears (Figures 1E and S1E), pectus carinatum and short
stature.
Patient 284672 was recruited to the DDD study together with
her elder affected sister (284673). Loeys-Dietz syndrome, myotonic
dystrophy and facioscapulohumeral muscular dystrophy were pro-
posed as potential diagnoses but genetic testing for these condi-
tions did not detect any pathogenic variants (Table S6). Although
nemaline myopathy was considered another possibility, prior analy-
sis of NEB (NM_001271208.1) had been limited to testing for a
founder deletion involving exon55.22 Exome sequencing identified
rare biallelic variants in NEB in both siblings: c.78+1G>A in trans
with a novel c.21489-21493dupGACTG; p.A7165fs*84. In addition
to these NEB variants, the younger sister (284672) was found to
harbour the c.628C>T; p.R210* variant in LZTR1 in trans with a
c.1735G>A; p.V579M VUS. The older sister had not inherited both
LZTR1 variants. Our interpretation of data from this family is there-
fore that while both girls have nemaline myopathy, the younger sib-
ling has a more complex “blended” phenotype due to additional
biallelic variants in LZTR1. Consistent with this hypothesis, we note
that features specific to the younger sibling include hypertelorism,
pointed chin, webbed neck, a broad chest, pectus excavatum,
mitral-valve abnormalities and abnormal nuchal translucency scan
results during pregnancy. Comparison of facial features is also con-
sistent with the younger sibling having a more NS-like gestalt
(Figure 1F-G, Figure S1F-G).
3.5 | Phenotype comparisons using unbiased HPO
terms
To help support that the LZTR1 variants were of clinical relevance, we
tested whether the patients identified above were more similar than
expected by chance. Comparison of HPO terms for the four patients
in whom trio exome analysis had uncovered de novo dominant muta-
tions in KT1-4 domains of LZTR1 showed significant phenotypic simi-
larity (Table 1; P = 0.0478). Singleton patient 269172 was excluded
from this analysis as prioritisation of this case from a group of single-
tons had included review of phenotype information. Comparison of
the three patients with compound-heterozygous variants also showed
a degree of similarity, although this did not reach a formal level of sig-
nificance (P = 0.0629), as reported previously.19 Grouping the AD and
AR cases together increased the significance levels of phenotypic sim-
ilarity (P = 0.0019). Finally, we removed the AR patient (284672) with
biallelic mutations in NEB (as well as LZTR1) as we believed this
patient to have a “blended” phenotype, with features such as myopa-
thy and ptosis more likely due to NEB. This comparison of the
remaining six cases further increased levels of similarity (P = 0.0005).
3.6 | Biallelic LZTR1 variants in 3/8 patients with a
clinical diagnosis of NS
Our second mutation detection strategy involved Sanger sequencing
of LZTR1 in seven unrelated patients with a diagnosis of NS and one
with the clinically overlapping Costello syndrome. These patients had
all tested negative for multiple NS genes. Aiming to enrich the cohort
for AR forms of NS, six of these cases had been selected either due to
documented consanguinity or because of the presence of affected
siblings.
Patient O1409410 is a male with classic NS facial features
(Figures 1H and S1H). In this individual, we identified compound-
heterozygous variants c.1311G>A; p.W437* and c.-38 T>A (Table 1);
the latter introduces an alternative ATG codon out-of-frame with the
canonical start site. Such features in mRNA, also known as upstream
open reading frames (uORFs), can cause widespread protein expres-
sion changes in humans,23 in some cases resulting in disease.24,25 We
therefore speculated that c.-38T>A might alter the amount of wild-
type LZTR1 protein. Using a 100 bp sequence spanning the canonical
start site and the c.-38T>A locus we ran ATGpr/TISminer on wild-type
and mutant sequences. This analysis suggested that, while both sites
have an equally strong identity with the [A/G]XXATGG Kozak consen-
sus sequence, the novel ATG could have a higher reliability in initiating
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translation (Supplementary note 2). A reporter assay using a dual lucif-
erase strategy was performed, as described.23,25 The ratio of renilla to
firefly luciferase was consistently reduced to 77% to 85% for the
mutant 5’-UTR in comparison to the WT (Supplementary note 2). AR
inheritance had been suspected in this family as a male sibling (despite
normal early scans) developed polyhydramnios at 20 weeks gestation.
Severe fetal hydrops ensued and an emergency cesarean section was
performed at 38 weeks due to reduced fetal movements. The baby
died shortly after delivery. A postmortem showed an increased heart
mass of 24.6 g (normal 16.4 ± 5.7 g) but no structural abnormality.
Histology of skeletal and cardiac muscle showed an excess of muscle
spindles, noteworthy given reports of such anomalies in Costello syn-
drome.26 Sanger sequencing indicated that this individual harbored
both variants, while an unaffected sister did not.
Patient O1409412, a female with milder NS-like features
(Figures 1I and S1I) and severe hypertrophic cardiomyopathy, har-
bored compound-heterozygous variants; c.1407G>A; p.W469* and a
c.2246A>G; p.Y749C VUS. Allele-specific PCR (Table S1) was used to
indicate these variants lay in trans, later confirmed by testing parental
DNAs. Again, AR inheritance had been suspected in this family as a
male sibling born at 34/40 weeks had hypertrophic cardiomyopathy
and died at 18 months. DNA for this individual was unavailable for
testing.
Patient O1504902 harbored two rare missense VUSs 3 bp apart
(c.1382C>A; p.A461D and c.1385T>C; p.I462T). Allele-specific PCR
confirmed that the two variants lay in trans (Figure S2). This girl was
born to unaffected non-consanguineous parents, has cardiac hyper-
trophy and a NS-like appearance. No pathogenic variants were
detected in several other NS-related genes. A younger unaffected sis-
ter has not been tested. Sanger sequencing of LZTR1 in the other five
patients did not reveal any significant variants.
3.7 | Clinical comparison and Face2Gene analysis
Review of available photographs indicates that a depressed nasal
bridge in young children with narrow nasal root and broad nasal tip in
older children are characteristic features of LZTR1-associated NS. In
AD cases it appears that the face may elongate with age (Figure 1A,
C). Analysis of photos using the Face2Gene tool (www.face2gene.
com) showed that for 8/10 patients where photographs were
obtained, NS ranked highest for at least one age (Table 1). For 4/8 of
these matches, there was a high degree of similarity to NS (Figure S1).
Based on a patient described by Johnston et al15 and a subse-
quent case report, it was suggested that the phenotype seen in
LZTR1-associated NS may sometimes include growth hormone
(GH) deficiency.27 The case-series reported here supports this hypoth-
esis as 287232 had GH deficiency, with a GH stimulation test showing
only borderline responses and no rare variants were detected in
40 other genes linked to GH deficiency.
In the original LZTR1 report, cardiac abnormalities mainly involved
pulmonary stenosis.9 Only 287232, O1504902 and III-1 have pulmo-
nary stenosis in this case-series, with the most common cardiac
abnormality being hypertrophic cardiomyopathy, reported in 3/10 AD
and 4/6 AR cases, respectively (Table S2 and S6).
4 | DISCUSSION
In the present study, a systematic analysis of exome data from a large
cohort of patients with developmental disorders identified LZTR1
mutations in ~0.1% (9/9624) of cases. For 8 individuals the LZTR1
variant(s) are likely causative and in one further case we hypothesise
LZTR1 is contributing to a “blended” phenotype. This figure may be an
underestimate, given that non-coding variants such as c.-38T>A are
poorly captured by exome sequencing. Patients where deletions of
<1 Mb are playing a role would also have been overlooked due to the
filtering pipeline employed.
Yamamoto et al9 suggested AD-acting mutations are most likely
to occur in the KT1-4 protein interaction domains, in particular KT4.
Consistent with this, we identified de novo mutations at residues p.
S244 and p.G248 (Figure 2C). The two de novo mutations involving p.
Y136 (Figure 2B) may represent a novel hotspot. Further studies
describing other de novo disease-causing mutations will help refine
the regions implicated in the AD form of NS. A recent structural analy-
sis of LZTR1 indicates that AD-acting variants typically lie on the top
surface of a six-blade propeller-like structure.28 Most de novo variants
identified here fit with that pattern, however p.R97L and the familial
p.N145I are buried toward the side of the propeller structure; we sus-
pect these may abrogate phosphorylation (Supplementary note
3, www.matteoferla.com/LZTR1.html). In the AR form, compound-
heterozygosity often involves a LoF allele in trans with a presumed
hypomorphic variant, with mutations typically spread across the gene
(Figure 2D). The exception to this rule was O1504902 who harbored
missense variants at adjacent codons (Figure S2).
The clinical team responsible for O1504902 could not find (as of
April 2018) any accredited UK laboratories offering LZTR1 testing as
part of a NS service, despite the fact LZTR1 was first associated with
NS >3 years ago.9 This highlights the variable lag time for inclusion of
new genes on panels and hence the advantages of using an exome
sequencing approach. Together with the 4/50 incidence seen in a Bra-
zilian cohort,9 the 3/8 detection rate obtained from our targeted
sequencing approach emphasises the importance of updating
NS/RASopathy panels to include this gene. This is further supported
by the ClinGen Expert Panel's recent assessment of 19 genes associ-
ated with various RASopathies where the evidence for LZTR1 was cat-
egorised as strong.7 Virtual gene-panels (curated gene-lists used to
filter variants detected by exome/WGS analysis) are more readily
updatable. For instance, the RASopathy panel in PanelApp (https://
panelapp.genomicsengland.co.uk/panels/48/) revised the mode of
inheritance for LZTR1 from monoallelic to monoallelic/biallelic just
6 weeks after publication.15
NS is part of a clinical spectrum of conditions which include
Noonan-like disorders due to mutations in SHOC2, PPP1CB and
CBL, Costello syndrome caused by HRAS mutations and
cardiofaciocutaneous syndrome caused by disruption of BRAF,
MAP2K1 and MAP2K2. These disorders all result from dysregulation
of RAS-MAPK signalling so have collectively been termed the
“RASopathies”. LZTR1 has only recently been functionally linked to
RAS-MAPK signalling,20,28–30 which explains why its role in NS long
went unrecognised. For instance, the gene was absent from a list of
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789 RAS–ERK pathway genes prioritised by Chen et al8 such that the
pathogenicity of p.R237Q/p.A249P identified in that study was only
realised subsequently.9 Recent work by Motta et al indicates that mis-
sense alterations associated with AR inheritance typically influence
protein synthesis/stability or subcellular localization. In contrast,
mutations associated with the AD form are expressed normally but
enhance EGF-dependent ERK1/2 phosphorylation.28 Functional stud-
ies such as these are especially important for the missense alterations
described here where pathogenicity has not been conclusively
established (Table S7, Supplementary note 4).
The c.-38T>A variant we identified leads to a uORF. Several
examples exist in the literature of disease-causing variants in 5-‘UTRs
and reporter gene assays such as the one used here are commonly
used to confirm the effect of such variants upon translation. Examples
include a de novo c.-107G>A variant in SLC2A1 found in a patient
with glucose transporter deficiency syndrome and c.-263C>A/c.-
255G>A variants in TWIST1 in patients with Saethre-Chotzen
syndrome.24,25
Using a combination of parent-child exomes and allele-specific
PCR showed that 5/5 de novo mutations reported here occurred on
the paternal chromosome. Although a larger case-series is required to
reach significance, these results are notable given mutations in
PTPN11 and other RAS-MAPK genes can influence spermatogonial
selection and predominantly occur on the paternal chromosome.31 A
2004 study phased 14 de novo mutations in PTPN11 and found all
originated on the paternal haplotype.11 The mean paternal age in that
PTPN11-positive cohort was 35.6 years, 2.2 years above that for the
PTPN11-negative cases and 6.1 years older than the population aver-
age. Increased paternal age at conception and a similar bias in the
parental origin of de novo HRAS mutations have been documented in
patients with Costello syndrome.32,33 For the five cases with de novo
LZTR1 mutations described here, paternal ages at childbirth were also
elevated (mean = 35.8, Table S5) compared with the average across
this DDD datafreeze (mean = 32.6).
A recent study focussing on fetal malformations detected in utero
identified a case of non-immune hydrops fetalis with a homozygous
variant in LZTR1.34 Fetal hydrops was also observed in 4 non-liveborn
siblings described by Johnston et al.15 Together with siblings of
O1409410/O1409412, these results indicate that LZTR1 mutations
can result in a much more severe form of disease. Further studies
should aim to uncover the reasons for this extreme variability and
whether such lethal presentations of disease can also be associated
with the AD form of LZTR1-associated NS.
Combining our results with those described in the
literature,9,15,20,27 hypertrophic cardiomyopathy was reported in 5/26
of individuals with AD-acting mutations but 19/26 of those
harbouring biallelic variants (Tables S2 and S6). A systematic analysis
of cardiac involvement in larger clinical cohorts of patients with LZTR1
mutations is warranted to confirm whether this bias is reproducible.
In conclusion, our study strengthens the association of LZTR1
with AD/AR forms of NS. In the dominant condition, mutations cluster
around the KT1-4 domains. In the AR form, compound-heterozygosity
often involves a LoF allele in trans with a presumed hypomorphic vari-
ant. Although LZTR1 mutations explain only ~0.1% of cases in the
DDD study, the gene is a notable cause of unsolved NS cases, espe-
cially where recessive inheritance is suspected.
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